Invesaro

Stocks Health care USNA

NYSE · Health care

Usana Health Sciences Inc (USNA)

Usana Health Sciences Inc brought in $913.4M of revenue over the twelve months to July 4, 2026, up 1.6% from a year earlier. It posted a net loss of $22.2M. Operating cash flow minus capital spending left $8.5M of free cash flow in fiscal 2025. At July 4, 2026 it held $168.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price
$14.50
+1.68% on the day · September 25, 2026
52-week range $12.57 to $28.52
Market cap
$267.9M
Revenue (last 12 months)
$913.4M
+1.6% year on year
Net margin
-2.4%
P/E
25.0
on FY2025 diluted EPS

What Usana Health Sciences Inc does

Usana Health Sciences Inc is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NYSE under the ticker USNA.

Revenue and profit by year

Revenue
FY18: $1.2B $1.2B FY18FY19: $1.1B $1.1B FY19FY20: $1.1B $1.1B FY20FY22: $1.2B $1.2B FY22FY22: $998.6M $998.6M FY22FY23: $921M $921M FY23FY23: $854.5M $854.5M FY23FY25: $925.3M $925.3M FY25
Net income
FY18: $126.2M $126.2M FY18FY19: $100.5M $100.5M FY19FY20: $124.7M $124.7M FY20FY22: $116.5M $116.5M FY22FY22: $69.4M $69.4M FY22FY23: $63.8M $63.8M FY23FY23: $42M $42M FY23FY25: $10.8M $10.8M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$925.3M$37.4M$10.8M$0.58$8.5M
2023$854.5M$66.3M$42M$2.19$50.9M
2023$921M$93.1M$63.8M$3.30$56.1M
2022$998.6M$107.6M$69.4M$3.59$93.5M
2022$1.2B$170.2M$116.5M$5.73$108.5M
2020$1.1B$176.5M$124.7M$5.86$145.3M
Next report expected around October 8, 2026.

Estimated from its filing rhythm: 52 weeks after its report of October 9, 2025. Not a date the company has announced. See the report calendar

Where USNA ranks in Health care

Revenue$925.3M
#150 of 523 in Health care · Top 29%
Revenue growth+8.3%
#266 of 437 in Health care · Bottom 39%
Net margin1.2%
#178 of 447 in Health care · Top 40%
Free cash flow margin0.9%
#198 of 408 in Health care · Top 48%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Usana Health Sciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 13, 2026
    Passive stake changed SCHEDULE 13G/A
  2. August 13, 2026
    Quarterly report 10-Q · period to July 4, 2026
  3. August 4, 2026
    Quarterly results 8-K
  4. June 15, 2026
    Employee plan annual report 11-K
  5. May 20, 2026
    Shareholder vote results 8-K
  6. May 12, 2026
    Quarterly report 10-Q · period to April 4, 2026
  7. May 5, 2026
    Quarterly results 8-K
  8. April 7, 2026
    Annual report to shareholders ARS
  9. April 7, 2026
    Proxy statement DEF 14A
  10. March 30, 2026
    Activist stake changed SCHEDULE 13D/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 27, 2026. Insider transactions on SEC

What is USNA worth? A DCF from its reported cash flow

Insider trades

What the people running Usana Health Sciences Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about USNA

What does Usana Health Sciences Inc do?

Usana Health Sciences Inc is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NYSE under the ticker USNA.

Is Usana Health Sciences Inc profitable?

No. Over the twelve months to July 4, 2026 it reported a net loss of $22.2M on revenue of $913.4M.

How much revenue does Usana Health Sciences Inc make?

Over the twelve months to July 4, 2026 Usana Health Sciences Inc reported revenue of $913.4M. That is 1.6% more than a year earlier.

When did Usana Health Sciences Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to July 4, 2026.

Similar companies

TRLV
Trulieve Cannabis Corp.
SNDL
SNDL Inc.
TLRY
Tilray Brands, Inc.
ACB
Aurora Cannabis Inc
CRON
Cronos Group Inc.
BTMD
biote Corp.

Compare USNA with

USNAvsTRLV
Trulieve Cannabis
USNAvsTLRY
Tilray Brands
USNAvsCRON
Cronos
USNAvsBTMD
biote
USNAvsGLAS
Glass House Brands

Compare USNA with any company

Follow USNA

Get an email when Usana Health Sciences Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow USNA: get an email when it files

Where the numbers come from

Financial figures are the values Usana Health Sciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.